RESEARCH TRIANGLE PARK, N.C., May 09, 2024 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced new real-world evidence on the use of oral, once-daily ORLADEYO® (berotralstat) demonstrating that patients with hereditary angioedema (HAE) in the United States experience significant reductions in healthcare resource utilization (HRU) after beginning treatment with ORLADEYO. The study was presented in a poster at the 2024 International Society for Pharmacoeconomics and Outcomes Rese ...

Table of Contents Title of each class Trading Symbol(s) Name of each exchange on which registered Common Stock BCRX Nasdaq Global Select Market UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 or o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ______________________ to ...

A better-than-expected first quarter and a goal of profitability and positive cash flow by the end of 2025 brought on a bit of a rally.For the most part, U.S. stocks had a good Monday, with the bellwether S&P 500 index confidently marching more than 1% higher. But BioCryst Pharmaceuticals (BCRX 18.43%) and its investors had a really good day, as the company delivered a first quarter that convincingly beat analyst estimates.The market rewarded this performance by pushing BioCryst's share price more than 18% ...

财务数据和关键指标变化 - 第一季度总收入为9,280万美元,其中ORLADEYO收入为8,890万美元,同比增长30% [29][30] - ORLADEYO在美国的收入为8,000万美元,占总收入的90%,其余10%来自海外市场 [29] - 公司预计第二季度ORLADEYO收入将达到9,700万美元,全年收入指引上调至3.9-4亿美元 [29][33] - 经营费用(不含股票激励)为9,360万美元,同比增加1,040万美元,其中包括130万美元的一次性重组费用 [30][31] - 剔除非现金股票激励后,第一季度经营亏损不到100万美元 [31] - 季末现金余额为3.384亿美元,第一季度现金消耗5,240万美元,其中包括320万美元的重组费用和690万美元的专利权使用费 [32] 各条业务线数据和关键指标变化 - ORLADEYO在美国的销售表现强劲,新患者处方量连续两个季度创下自2021年上市以来的最佳水平 [7][13] - 公司认为ORLADEYO在美国的峰值收入可达8亿美元,全球峰值收入可达10亿美元 [8][16] - 欧洲市场ORLADEYO患者增长强劲稳定,西班牙和意大利的新市场也开始为公司贡献收入 [16] - 日本团队自2024年初正式到位,公司对其早期影响感到鼓舞 [16] 各个市场数据和关键指标变化 - 美国市场ORLADEYO收入占总收入的90%,同比增长30% [29] - 欧洲市场ORLADEYO收入占总收入的10% [29] - 公司预计未来几年内,海外市场ORLADEYO收入占比将继续增加,但美国市场仍将是主要收入来源 [43][44] 公司战略和发展方向及行业竞争 - 公司正在积极推进ORLADEYO在儿童适应症的开发,预计2025年提交注册申请 [20] - 公司正在推进BCX10013、BCX17725和avoralstat等管线项目,预计未来18个月内将有多个项目进入临床试验 [21][23][24] - 公司正在开发针对补体系统的多个靶点的候选药物,包括蛋白质治疗药物和口服小分子药物 [25] - 公司管理层对ORLADEYO在全球市场的增长前景以及管线项目的发展前景表示乐观 [7][8][9][16] 管理层对经营环境和未来前景的评论 - 公司管理层认为ORLADEYO在美国市场的销售势头良好,患者和医生对其疗效和便利性的认可度不断提高 [13][41][42] - 公司管理层预计ORLADEYO在美国和全球市场的峰值收入目标可实现,并有望在未来几年内实现盈利 [8][33] - 公司管理层对ORLADEYO在儿童适应症和管线项目的发展前景表示乐观 [20][21][23][24][25] 问答环节重要的提问和回答 问题1 **Maury Raycroft 提问** 公司如何区分易于和困难的处方再授权,并计划如何利用这些经验来提高效率? [47] **Charlie Gayer 回答** 公司投资改善患者服务和市场准入团队,以提高处方再授权的效率。易于再授权的患者是因为支付方已有完整的病史和检查数据,而困难的则是支付方要求重复提供这些信息。公司将继续优化这一过程,预计未来几年内可达到85%的付费率目标。 [48][49][50] 问题2 **Liisa Bayko 提问** 公司是否包括日本的ORLADEYO收入在内的10%海外收入? [75][76][77][78] **Anthony Doyle 回答** 是的,8,890万美元的ORLADEYO收入包括了日本的ORLADEYO收入。公司不会单独披露各个国家的收入细节。 [78] 问题3 **Gena Wang 提问** 公司在日本市场的ORLADEYO价格是否也有30%-50%的折扣,类似欧洲市场? [99] **Charlie Gayer 回答** 公司对日本市场的长期预期很乐观,认为未来5-10年内这个市场将持续增长。目前公司正专注于提高已诊断患者中预防治疗和口服预防治疗的使用率,并提高对ORLADEYO的认知度。 [95]

First Quarter 2024 Results Call Corporate Update & Financial Results May 6, 2024 ...

BioCryst Pharmaceuticals (BCRX) came out with a quarterly loss of $0.17 per share versus the Zacks Consensus Estimate of a loss of $0.23. This compares to loss of $0.28 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 26.09%. A quarter ago, it was expected that this drugmaker would post a loss of $0.24 per share when it actually produced a loss of $0.28, delivering a surprise of -16.67%.Over the last four quarters, the company ...

EXHIBIT 99.1 BioCryst Reports First Quarter 2024 Financial Results and Provides Business Update —Q1 2024 ORLADEYO net revenue grows 30 percent y-o-y to $88.9 million— —Full-year 2024 ORLADEYO revenue guidance adjusted to $390-$400 million (top end of prior guidance range) — —Pipeline programs, including BCX17725 for Netherton syndrome and avoralstat for DME, advancing on schedule into clinical trials— RESEARCH TRIANGLE PARK, N.C., May 06, 2024 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq:BCRX) ...

Wall Street expects a year-over-year increase in earnings on higher revenues when BioCryst Pharmaceuticals (BCRX) reports results for the quarter ended March 2024. While this widely-known consensus outlook is important in gauging the company's earnings picture, a powerful factor that could impact its near-term stock price is how the actual results compare to these estimates.The stock might move higher if these key numbers top expectations in the upcoming earnings report, which is expected to be released on ...

公司业绩公布 - BioCryst Pharmaceuticals将于2024年5月6日公布第一季度财务业绩[1] - 公司管理层将在当天上午8:30举行电话会议和网络直播，讨论财务业绩并提供公司更新[2] 公司背景介绍 - BioCryst Pharmaceuticals是一家全球生物技术公司，致力于改善患有补体介导和其他罕见疾病的患者生活，公司利用结构引导药物设计的专业知识开发首创或最佳口服小分子和蛋白质治疗药物，已经推出ORLADEYO®（berotralstat）并正在推进一系列小分子和蛋白质疗法的研发[4]

ORLADEYO获得批准 - BioCryst Pharmaceuticals宣布ORLADEYO（berotralstat）获得巴西卫生监管机构批准，用于预防成人和12岁及以上儿童的遗传性血管性水肿（HAE）发作[1] 合作与推广 - 与Pint Pharma GmbH独家合作，在整个拉丁美洲地区注册和推广ORLADEYO[3] 专门设计口服疗法 - ORLADEYO（berotralstat）是首个也是唯一一个专门设计用于预防成人和12岁及以上儿童遗传性血管性水肿（HAE）发作的口服疗法[4]